Balance the risk of stroke versus the risk of bleeding
There was good news recently in the atrial fibrillation world.
Though no surprise to heart rhythm doctors, an FDA investigation reveals no evidence that new cases of bleeding are any higher with dabigatran (Pradaxa) than with warfarin.
The full statement from the FDA is here.
The assessment was undertaken because after approval of the novel anticoagulant (blood-thinner) a large number of adverse events were reported to the FDA. Despite conscientious medical …
Balance the risk of stroke versus the risk of bleeding

















